A medical imaging system configured to provide cardiac sonothrombolysis therapy is disclosed. Various embodiments of portable cardiac sonothrombolysis devices are disclosed. The devices may be configured to determine if one or more ultrasound probes have a proper view of the heart, and if not, may steer the beam to a desired location. The ultrasound probes may be configured for both imaging and cardiac sonothrombolysis therapy. The ultrasound probes may be configured to be hands-free. The portable devices may be configured to provide operating instructions to an operator. The instructions may be provided via graphics, audio, and/or video.

An acoustic module with a transducer and a solid waveguide. The transducer and waveguide may be curved to focus the acoustic energy along a focal line. The transducer, the top surface of the waveguide and the bottom surface of the waveguide may extend along coaxial curves. The waveguide may include a recess closely receiving the transducer. The waveguide may include an integral skirt that provides a thermal mass. The acoustic module may include a space to accommodate thermal management options. For example, the acoustic module may include a heatsink, an active ventilation system and/or a phase change material. The ultrasound device may include a controller configured to perform a uniformity scan sweep during supply of operating power to the transducer. The uniformity scan sweep can extend through a frequency range that includes the operating point of the acoustic module and does not exceed an acceptable efficiency loss.

The invention discloses a method and a device to treat vessels. In particular, the invention is directed at a method to occlude varicose veins while avoiding the formation of bubble clouds in the tissue surrounding the vessel and/or their interaction with the ultrasound beam. The invention is further directed at a device adapted to perform the method.

An ablation catheter comprises: an elongated catheter body extending longitudinally between a proximal end and a distal end along a longitudinal axis; a distal member disposed adjacent the distal end, the distal member including an ablation element to ablate a biological member; one or more acoustic transducers disposed in the distal member and each configured to direct an acoustic signal toward a respective target ablation region and receive reflection echoes therefrom; and an acoustic redirection member disposed in the distal member to at least partially redirect the acoustic signal from at least one of the acoustic transducers toward a tissue target. The distal member includes a most-distal portion, a proximal portion, and a deflectable portion between the most-distal portion and proximal portion to permit deflection between the most-distal portion and proximal portion of the distal member. The transducers and redirection member are mounted on opposite sides of the deflectable portion.

A method for performing spectral analysis and determining a safety marker includes an assembly via which: regularly, during shot Bb, at a series of times ta, the variation as a function of time in the spectral lines corresponding to the subharmonic and ultra-harmonic frequencies of a received acoustic-response signal of the microbubbles is measured, and the variation as a function of time, over the times ta, in a safety marker is determined and quantified, the safety marker being defined, at each time ta, by a number MDDa equal to the ratio of the sum of the areas of the spectral lines, measured at the time ta and corresponding to the subharmonic and/or ultra-harmonic frequencies of the received acoustic-response signal of the microbubbles, to the sum of the areas of the spectral lines, measured at the first time t1 and corresponding to the subharmonic and/or ultra-harmonic frequencies of the acoustic-response signal of the microbubbles. A system for performing spectral analysis and determining a safety marker implements said method.

A support structure for placement on or about a subject's head supports an ultrasound transducer array configured to deliver transcranial stimulation to a specified region or regions of the subject's brain using pre-recorded neurostimulation data. The pre-recorded neurostimulation data comprises patterns of stimulation of the specified region or regions of the subject's brain or other person's brain developed to recreate a response by one or more of a sensing organ or sensing organs, a vestibular system, and a memory of the subject. A magnetic sensor array is mounted to the support structure and configured to transcranially sense local magnetic fields emanating from the specified region or regions of the subject's brain caused by delivery of the transcranial stimulation and produce contemporaneous neurostimulation data developed using the transcranially sensed local magnetic fields. Electronic circuitry comprising a controller is configured to control operation of the respective arrays.

The present invention relates to an implantable ultrasound (US) generating device for implantation within the vertebral column of a vertebrate subject, wherein the implantable US generating device comprises at least one US generating transducer suitable for emitting US beam(s) with an oblique orientation with respect to a longitudinal axis of a vertebral column.

The present disclosure describes a method for detecting and treating a low grade malignant tissue in a subject, comprising administering 5-aminolevulinic acid or a pharmaceutically acceptable salt or ester thereof, to the subject and measuring the fluorescence of the tissue.

One or more ultrasonic transducers are driven to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue.

Embodiments are provided that enhance ultrasound efficacy by for example, high efficiency, signal measurement, calibration, and assurance systems with a control system radio-frequency (RE) driver configured to drive one or more focused ultrasound transducers. The RE driver can comprise one or more power amplifiers including one or more III-V semiconductors, (e.g., gallium nitride GaN, GaAs, GaSb, InP, InAs, InSb, InGaAs, AlSb, AlGaAs, and/or AlGaN) field-effect transistors to efficiently provide high power with distinct narrow-band RE signals over a wide frequency range. The RE driver can include a power measurement and/or calibration system to monitor the amplitude and phase of the RE signal output from the power amplifier and estimate the amount of RE power delivered to the ultrasound transducers.